Inversago is a privately owned company which develops therapies pitched at people with obesity, diabetes and metabolic disorders, the Novo Nordisk said in its second-quarter report. Inversago's lead asset is INV-202, a cannabinoid receptor blocker, which has shown weight loss in a phase 1b trial and is now in phase 2 development.
from Top Health News | Latest Healthcare Sector & Healthcare Industry news, Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/Qm6Vi95
Home »
Information and Updates: ET HealthWorld : ETHealthworld.com
,
Top Health News | Latest Healthcare Sector & Healthcare Industry news
» Novo Nordisk to acquire obesity drug developer Inversago
https://ift.tt/sQqlMJu
No comments:
Post a Comment